| Host: |
Goat |
| Applications: |
Pep-ELISA/IHC/ICC |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Goat polyclonal antibody anti-CEP290 (Internal) is suitable for use in ELISA, Immunohistochemistry and Immunocytochemistry research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
| Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Concentration: |
0.5 mg/mL |
| Dilution Range: |
IHC-5-7µg/mlELISA-antibody detection limit dilution 1:128000. |
| Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
| Gene Symbol: |
CEP290 |
| Gene ID: |
80184 |
| Uniprot ID: |
CE290_HUMAN |
| Immunogen Region: |
Internal |
| Accession Number: |
NP_079390.3 |
| Specificity: |
Despite similarity of the immunizing peptide with the mouse protein, this antibody was demonstrated to weak for mouse Cep290. |
| Immunogen Sequence: |
RNSKHLKQQQYRAEN |
| Post Translational Modifications | Ubiquitinated. May undergo monoubiquitination.monoubiquitination is inhibited in response to cellular stress, such as ultraviolet light (UV) radiation or heat shock, but does not cause its displacement from centriolar satellites. |
| Function | Involved in early and late steps in cilia formation. Its association with CCP110 is required for inhibition of primary cilia formation by CCP110. May play a role in early ciliogenesis in the disappearance of centriolar satellites and in the transition of primary ciliar vesicles (PCVs) to capped ciliary vesicles (CCVs). Required for the centrosomal recruitment of RAB8A and for the targeting of centriole satellite proteins to centrosomes such as of PCM1. Required for the correct localization of ciliary and phototransduction proteins in retinal photoreceptor cells.may play a role in ciliary transport processes. Required for efficient recruitment of RAB8A to primary cilium. In the ciliary transition zone is part of the tectonic-like complex which is required for tissue-specific ciliogenesis and may regulate ciliary membrane composition. Involved in regulation of the BBSome complex integrity, specifically for presence of BBS2, BBS5 and BBS8/TTC8 in the complex, and in ciliary targeting of selected BBSome cargos. May play a role in controlling entry of the BBSome complex to cilia possibly implicating IQCB1/NPHP5. Activates ATF4-mediated transcription. |
| Protein Name | Centrosomal Protein Of 290 KdaCep290Bardet-Biedl Syndrome 14 ProteinCancer/Testis Antigen 87Ct87Nephrocystin-6Tumor Antigen Se2-2 |
| Database Links | Reactome: R-HSA-2565942Reactome: R-HSA-380259Reactome: R-HSA-380270Reactome: R-HSA-380284Reactome: R-HSA-380320Reactome: R-HSA-5620912Reactome: R-HSA-6798695Reactome: R-HSA-8854518 |
| Cellular Localisation | CytoplasmCytoskeletonMicrotubule Organizing CenterCentrosomeCentriolar SatelliteNucleusCell ProjectionCiliumCilium Basal BodyCentrioleCytoplasmic VesicleDisplaced From Centriolar Satellites In Response To Cellular StressSuch As Ultraviolet Light (Uv) Radiation Or Heat ShockFound In The Connecting Cilium Of Photoreceptor CellsBase Of Cilium In Kidney Intramedullary Collecting Duct CellsLocalizes At The Transition ZoneA Region Between The Basal Body And The Ciliary AxonemeLocalization At The Ciliary Transition Zone As Well As At Centriolar Satellites Is Bbsome-Dependent |
| Alternative Antibody Names | Anti-Centrosomal Protein Of 290 Kda antibodyAnti-Cep290 antibodyAnti-Bardet-Biedl Syndrome 14 Protein antibodyAnti-Cancer/Testis Antigen 87 antibodyAnti-Ct87 antibodyAnti-Nephrocystin-6 antibodyAnti-Tumor Antigen Se2-2 antibodyAnti-CEP290 antibodyAnti-BBS14 antibodyAnti-KIAA0373 antibodyAnti-NPHP6 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
